RE: CV results19 Mar 2021 11:46
NOOOOOO NOOOOO NOOOOO you don't get away with it that easily VC.
Can you explicitly point me to where AVCT said they were making a Zika test? No because that was NEVER STATED.
At no point in the below does it say AVCT are developing a test for ZIKa. It sys there was potential. There was no demand so it simply became a proof of concept for the Affimer platform - not a commercial opportunity. There was no test to fail you muppet! What did happen though, as has happened with COVid is they produced binding Affimers in quick time
The three Affimer binders are highly specific to the Zika NS1 protein and can differentiate in human serum from five other closely related viruses that give similar symptoms: Dengue, Yellow Fever, West Nile, and Japanese and Tick-borne Encephalitis. Since these viruses are very similar, there is currently no validated antibody that detects Zika virus specifically, which is a limiting factor in the development of a reliable, quick diagnostic test.
"The ability to rapidly generate new diagnostic reagents in response to outbreaks of infectious agents is critical to meeting an urgent medical need, as recently evidenced by the SARS and Ebola virus outbreaks. The very high specificity of Avacta’s Affimer technology, together with the speed with which new Affimer binders can be identified and characterised, makes the technology ideal for rapidly responding to the need for detection and monitoring of new outbreaks. The Group intends to commercialise Affimer based rapid diagnostics through co-development and licensing to third party diagnostics developers an example of which is Mologic, a UK rapid diagnostics developer, with whom a research and product development collaboration was recently announced. "
Sign In
Follow the stocks
